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The Editorial on the Research Topic
Human Tumor-Derived p53 Mutants: A Growing Family of Oncoproteins
Mutations in the tumor suppressor p53 gene are collectively the most common event in human 
cancers. These do not merely reflect a loss of the tumor suppressive function of wild type (wt) p53 
but are also selected during tumorigenesis for their acquired gain-of-function (GOF), together 
contributing to multiple hallmarks of cancer. Over 30 years of extensive study into wt p53 provided a 
wealth of information about its regulation, functions, and contribution to cancer prevention. Albeit, 
with a significant delay, the interest in mutant p53 has been growing fast over the past decade with 
the realization that most cancer patients present tumors with mutant p53, and these particularly 
manifest in aggressive and metastatic diseases. The growing understanding of mutant p53 exposes 
attractive therapeutic opportunities with wide clinical applications, which coincidently raise many 
challenging questions concerning associated complexities. In this research topic, we assembled 12 
reviews exposing some critical issues and discussing prospect development in this field.
One of the most commonly used mouse models for cancer is the p53 knockout mouse. However, 
this model of p53 deficiency does not represent the majority of human cancers. A major leap in 
the understanding of mutant p53 regulation and GOF was derived from mouse genetics (1, 2). The 
group of Lozano, which led the mouse models for mutant p53, highlighted the GOF learned from the 
comparison between p53 deficient mice and mutant p53 knock-in mice, primarily the contribution 
of mutant p53 to tumor metastasis (Kim et al.). The Lozano group also emphasized the biological 
and biochemical differences between different mutants, even between different substitutions of the 
same amino acid, such as p53R172H versus p53R172P. Hence, not all p53 mutants are equal. While 
the abovementioned mouse models for inherited p53 mutations (the Li–Fraumeni model), this 
represents a small fraction of p53 mutations in human cancers. This key point was discussed by the 
Lozano group highlighting the limitations of the current mouse models for sporadic p53 mutations 
in cancer. They discuss the problems with the current conditional mutant p53 models in which all 
cells are heterozygous for p53 from conception and hence do not faithfully mimic the role of mutant 
p53 in sporadic tumor development. These models lack the challenging context of the cells with wt 
p53 that normally comprise the tumor microenvironment and its inherent immune cells. There is a 
clear need for more sophisticated mouse models to better define the distinct roles of mutant p53 in 
these compartments. The Del Sal group (Walerych et al.) discussed the difference between the mouse 
and human mutant p53 exemplified by the p53R249S mutation, which exhibits GOF in human cells, 
but this had not been recapitulated in the relevant mouse model. A comprehensive list summarizing 
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studies from the last decade is provided in the Del Sal review 
outlining which mutants GOF effects have been validated and the 
associated information.
Mutant p53 GOF requires the accumulation of the mutant 
protein and that, at least initially, it acts dominantly over the 
wt protein. Sabapathy discussed this important point in detail, 
emphasizing the timing and conditions under which dominant 
negative (DN) effects of mutant p53 occur, and when and how 
this would impact on tumorigenesis. His conclusion from the 
literature is that stress, whether acute (e.g., genotoxic stress) or 
chronic (activated oncogene), accumulates mutant p53; however, 
it is under the latter conditions that mutant p53 promotes tumo-
rigenesis. Further complexity to this is the tissue specificity of 
the DN effect as learned from the KI heterozygote mouse models 
(Sabapathy). In the wake of the DN effect, there is often a loss 
of heterozygosity (LOH) of the wt allele. However, Walerych 
et  al. discussed that LOH is also tissue specific, as exemplified 
by the work of Rotter and coworkers demonstrating that, in the 
embryonic stem cells of the KI mutant p53 mice, the LOH can 
be of either wt or mutant p53 alleles, potentially acting to control 
cell fate checkpoint (3). This reflects the opposing effects of wt 
and mutant p53 on stem cell survival and plasticity (Sabapathy).
A major requirement for GOF by mutant p53 is a constant 
stabilization of the mutant p53 protein, unlike the temporal 
accumulation of wt p53. The review by Vijayakumaran et  al. 
summarizes the differences and similarities in the regulation of 
wt and mutant p53. While both wt and mutant p53 are inher-
ently labile proteins and accumulate in response to stress, only 
the mutant form remains stable. Intriguingly, wt and mutant p53 
share many of their regulatory mechanisms. However, the loss 
of the key negative autoregulatory loops due to mutation in p53 
result in the sustained accumulation of mutant p53 following 
stress conditions or exposure to oncogenic stress in cancer cells. 
This, together with a loss of specificity of additional E3 ligases 
toward mutant p53, provides an explanation for the accumula-
tion of mutant p53. The additional complexity of p53 regulation, 
both wt and mutant p53, by microRNA (miRNA) is presented 
Vijayakumaran et al. This reveals the ways by which p53 can be 
deregulated in cancer but, at the same time, may define potential 
new therapeutic targets.
Understanding the mechanisms by which mutant p53 gains 
its oncogenic functions are the subject of intensive research. 
While most of wt p53 activities are mediated through the tran-
scriptional activation of target genes, the apoptotic activity of p53 
also involves transcriptional independent activities. Giorgi et al. 
discussed the cytoplasmic apoptotic activities of wt p53, and the 
loss of these activities by mutations in p53. To date, there is no 
evidence for a GOF of mutant p53 directly regulating these activi-
ties (Giorgi et al.). On the other hand, it was reported that mutant 
p53 proteins can aberrantly cooperate with known transcription 
factors by leading to disregulated gene expression. This results 
in increased proliferation, invasion, genomic instability, and 
chemoresistance. The interaction of mutant p53 with p53 family 
members p63 and p73 is key to some of its GOF. Ferraiuolo et al. 
review the intricate relationship between mutant p53 and p63 or 
p73. Mutant p53 proteins can also hamper tumor suppression 
transcriptional programs by binding to and displacing the p53 
family members p73 and p63 from their consensus of target 
gene promoters (4). Collectively, the intra-p53 family protein 
complexes with their oncogenic activity may represent druggable 
targets, which hold therapeutic potential.
Beyond p53 family members, Haupt et al. reviewed the major 
tumor suppressive pathways, which are subverted by mutant p53, 
including PTEN, PLK2, and PML, which control the cell cycle 
and the latter also the circadian clock. Intriguingly, mutant p53 
deregulates cellular metabolism including glucose, lipid, and 
nucleotide metabolism, ensuring the sufficient supply of building 
blocks to support tumor growth (Haupt et  al.). How are these 
plethora of activities achieved by mutant p53? At least two major 
mechanisms have been reviewed in this series. First, is by con-
trolling gene expression through the alteration of specificity of 
certain transcription factors. Second, is by affecting chromatin 
remodeling through SWI/SNF and MLLs/MOZ (Haupt et al.). The 
effect of mutant p53 on MLLs/MOZ is achieved through ETS2, as 
reviewed in detail by Martinez. He discusses the mechanism by 
which mutant p53 protects ETS2 from degradation, and how this, 
in turn, affects the overall transcriptional effects of the ETS family 
and contributes to the oncogenic phenotype of mutant p53, such 
as increased nucleotide metabolic genes (Martinez). Bruno et al. 
reviewed the relationship of p53 with the cofactor Che-1/AATF. 
This provides an interesting example of a factor that acts as an 
activator and protector of both wt and mutant p53. In response 
to DNA damage, Che-1 induces the expression of wt and mutant 
p53, but activates wt p53 to induce growth arrest genes. In the 
case of mutant p53, it induces its expression and consequently the 
sequestration of p73 from apoptotic target genes, hence promotes 
survival (Bruno et al.).
A major consequence of mutant p53 GOFs is the acquired 
dependence of cancer cells on the expression of mutant p53. 
This dependence, which has been termed oncogenic addiction to 
mutant p53 has been discussed by multiple contributors to this 
series, highlighting its importance. Evidence for this addiction 
has been discussed by the Lozano, Sabapathy, and Del Sal groups. 
This addiction defines an Achilles Heal with important clinical 
implications. Parrales and Iwakuma highlighted the potential 
exploitation of heterozygosity, during which mutant p53 acts 
as a DN over wt p53, hence targeting mutant p53 eliminates its 
oncogenic driver and concurrently restores the tumor suppres-
sive capacity of wt p53. Parrales and Iwakuma provided a compre-
hensive review of mutant p53 as a druggable target. They discuss 
the different classes of mutant p53 drugs, including compounds 
that restore wt p53 activity in cells expressing mutant p53, with 
the leading drug APR-246 (see below); compounds that deplete 
mutant p53 expression, where HSP90, in particular Ganetespib, 
is the most advanced drug currently in phase III clinical trial; 
and explore other approaches, which are currently used for 
other oncogenes, including knockdown and read-through of 
premature termination (Parrales and Iwakuma). This review was 
complemented by two focused reviews on mutant p53 therapeu-
tics. The first by Bykov et al., which focused on the mechanism 
of action by APR-246, including the refolding of mutant p53, 
the impact on mutant isoforms of p53 family members p63 and 
p73 and the effect on the cellular redox regulators, primarily 
glutathione and thioredoxin, to enhance oxidative stress. The 
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potential of APR-246 as a single agent and in combination with 
DNA damaging agents is discussed, and the current clinical status 
of APR-246 and prospects are outlined (Bykov et al.). The second 
therapeutic review by Burgess et al. focused on MDM2/MDMX 
targeted therapies. This review provides a thorough overview 
of the current drugs and approaches to target p53 via MDM2 
and MDMX pathways. They outline the clinical development of 
current MDM2 targeting compounds. Importantly, they discuss 
the major hurdle in this approach, which is severe cytopenias. 
Although, this approach has not been designed to target mutant 
p53, the relevance of mutant p53 to this therapeutic approach 
and the availability of appropriate biomarkers were discussed 
(Burgess et al.).
CoNClUdiNG rEMarKS
Overall, this series of reviews on mutant p53 expose the pivotal 
role of mutant p53 as an oncogenic driver and outline the fast 
advancement in our understanding of its regulation and onco-
genic activities. Our deeper understanding of mutant p53 also 
highlights clear limitations, such as the differences between 
mutants p53 proteins and between mouse and human mutant 
p53. The lack of appropriate mouse models for somatic p53 
mutations, which represents the most common event in human 
cancer is a major hurdle to our understanding of mutant p53 
to the cancer cell versus the microenvironment. The series also 
reflects the excitement around the clinical opportunities and 
current clinical development but highlights the need of potent 
molecules to specifically target mutant p53, given its prevalence 
in human cancers. It has also been increasingly clear that mutant 
p53 proteins are not a single entity, but they behave as a family of 
oncoproteins whose deciphering and therapeutic tackling might 
impact enormously on the success of threatening the vast major-
ity of human cancers.
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